{"organizations": [], "uuid": "d3dad7de8653b6e2d81c3a21cc47be5c7453de8a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180328.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-nichi-iko-pharmaceutical-says-busi/brief-nichi-iko-pharmaceutical-says-business-and-capital-alliance-with-eisai-idUSL3N1RA32N", "country": "US", "domain_rank": 408, "title": "BRIEF-Nichi-Iko Pharmaceutical says business and capital alliance with Eisai", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-03-28T14:45:00.000+03:00", "replies_count": 0, "uuid": "d3dad7de8653b6e2d81c3a21cc47be5c7453de8a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-nichi-iko-pharmaceutical-says-busi/brief-nichi-iko-pharmaceutical-says-business-and-capital-alliance-with-eisai-idUSL3N1RA32N", "ord_in_thread": 0, "title": "BRIEF-Nichi-Iko Pharmaceutical says business and capital alliance with Eisai", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-nichi-iko pharmaceutical", "sentiment": "negative"}, {"name": "eisai", "sentiment": "negative"}, {"name": "reuters) - nichi-iko pharmaceutical co ltd", "sentiment": "neutral"}, {"name": "beijing headline news", "sentiment": "none"}, {"name": "eisai co ltd", "sentiment": "none"}, {"name": "elmed eisai co ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 28 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd\n* Says it forms business and capital alliance with Eisai Co Ltd\n* Says two entities will mainly cooperate on generic drug business model reform, ecosystem construction and API application\n* Says it will acquire 100 percent stake in ELMED EISAI Co Ltd from Eisai Co Ltd, for 17.12 billion yen in total\n* Says it plans to complete stake acquisition on April 1, 2019\nSource text in Japanese: goo.gl/qnso5S\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://goo.gl/qnso5S", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-28T14:45:00.000+03:00", "crawled": "2018-03-29T15:38:30.004+03:00", "highlightTitle": ""}